Upcoming event

FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?

March 2019

First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)

March 2019

IDENTIFY: The Investigation and DEtection of urological Neoplasia in paTIents reFerred with suspected urinarY tract cancer: A multicentre analysis

March 2019

Combining DNA-repair gene mutations and molecular subtyping for more accurate prediction of outcome after neoadjuvant chemotherapy for bladder cancer

March 2019

Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy

March 2019

Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)

European Urology, Volume 74, Issue 3, September 2018, Pages 294-306

Effectiveness of transurethral resection (TUR) plus systemic chemotherapy as definitive treatment for muscle-invasive bladder cancer (MIBC)

Journal of Urology, Issue 5, November 2018, Pages 996-1004

Prognostic implication of the United States Food and Drug Administration-defined BCG-unresponsive disease

European Urology, October 2018

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial

Lancet. 2018 Jun 23

Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy

European Urology, Volume 74, Issue 5, July 2018, Pages 540-544

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial

European Urology, September 2018

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

Journal of clinical oncology, Volume 36, December 2018

Next